Urinary multi-omics meets artificial intelligence in bladder cancer: from liquid biopsy to clinical decision-making

Bladder cancer is among the most recurrence-prone malignancies, and its management remains anchored to invasive cystoscopy and cytology, which have limited sensitivity. Urine, which is in direct contact with the tumor, carries a rich molecular cargo, including urinary tumor-derived DNA (utDNA), the tumor-derived fraction of urinary cell-free DNA, alongside methylation marks, extracellular vesicle (EV) cargo, and exfoliated cells. These components can now be interrogated through multi-omics profiling and interpreted using artificial intelligence (AI). In this Mini Review, we integrate these layers into a single translational framework: microfluidic “urine-on-chip” technologies convert a drop of urine into standardized, analysis-ready multi-omic data, while machine learning and deep learning models—increasingly governed by STARD-AI/TRIPOD + AI reporting standards—transform these data into diagnostic, prognostic, and treatment-response predictions. We highlight clinically mature anchors, including the utMeMA methylation assay (90.0%/83.1%), the Uromonitor mutation test (TERT/FGFR3/KRAS; 80.2%/96.9%, meta-analysis), chip-based cytometry for detecting high-grade disease, and an externally validated autonomous urine cytology system. These figures are assay-specific and should not be interpreted as platform-wide benchmarks. Finally, we define the priorities—pre-analytical standardization, external validation, and cost-effectiveness—that will advance urinary multi-omic AI from its current performance level into routine practice along a “detect–decide–treat–monitor” digital management pathway.

Authors

Institutions

Publication Details

Journal
Frontiers in Genetics
Published
2026-11-20
DOI
https://doi.org/10.3389/fgene.2026.2022740
Primary Topic
Bladder and Urothelial Cancer Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Urinary multi-omics meets artificial intelligence in bladder cancer: from liquid biopsy to clinical decision-making

Heng Xu, Juan Tang, Zhen Wu, Shengjun Xiao et al.
Frontiers in Genetics
Bladder and Urothelial Cancer Treatments
article

Urinary multi-omics meets artificial intelligence in bladder cancer: from liquid biopsy to clinical decision-making

Heng Xu, Juan Tang, Zhen Wu, Shengjun Xiao, Tianyi Liu, Liyuan Wu, Xiaokang Wang
article en

Abstract

Bladder cancer is among the most recurrence-prone malignancies, and its management remains anchored to invasive cystoscopy and cytology, which have limited sensitivity. Urine, which is in direct contact with the tumor, carries a rich molecular cargo, including urinary tumor-derived DNA (utDNA), the tumor-derived fraction of urinary cell-free DNA, alongside methylation marks, extracellular vesicle (EV) cargo, and exfoliated cells. These components can now be interrogated through multi-omics profiling and interpreted using artificial intelligence (AI). In this Mini Review, we integrate these layers into a single translational framework: microfluidic “urine-on-chip” technologies convert a drop of urine into standardized, analysis-ready multi-omic data, while machine learning and deep learning models—increasingly governed by STARD-AI/TRIPOD + AI reporting standards—transform these data into diagnostic, prognostic, and treatment-response predictions. We highlight clinically mature anchors, including the utMeMA methylation assay (90.0%/83.1%), the Uromonitor mutation test (TERT/FGFR3/KRAS; 80.2%/96.9%, meta-analysis), chip-based cytometry for detecting high-grade disease, and an externally validated autonomous urine cytology system. These figures are assay-specific and should not be interpreted as platform-wide benchmarks. Finally, we define the priorities—pre-analytical standardization, external validation, and cost-effectiveness—that will advance urinary multi-omic AI from its current performance level into routine practice along a “detect–decide–treat–monitor” digital management pathway.

Frontiers in GeneticsVol. 17
Guilin Medical University (CN), First Affiliated Hospital of Zhengzhou University (CN)
Bladder and Urothelial Cancer Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon